MCM
RXRX icon

MAI Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

MAI Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.69K Buy
1,854
+616
+50% +$2.38K ﹤0.01% 3446
2025
Q4 		$5.06K Hold
1,238
– – ﹤0.01% 3116
2025
Q3 		$6.04K Sell
1,238
-1,000
-45% -$5.25K ﹤0.01% 2946
2025
Q2 		$11.3K Buy
2,238
+845
+61% +$4.15K ﹤0.01% 2658
2025
Q1 		$7.37K Hold
1,393
– – ﹤0.01% 2604
2024
Q4 		$9.42K Buy
+1,393
New +$9.37K ﹤0.01% 2534

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MAI Capital Management's RXRX Position: Q1 2026 in Review

MAI Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 50% in Q1 2026, buying an estimated $2.38K and bringing the position to 1,854 shares worth $5.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.

MAI Capital Management first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $11.3K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • MAI Capital Management held 1,854 shares of Recursion Pharmaceuticals worth $5.69K as of Q1 2026.
  • MAI Capital Management bought 616 Recursion Pharmaceuticals shares in Q1 2026, an estimated $2.38K.
  • Recursion Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3446 holding.
  • MAI Capital Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Recursion Pharmaceuticals position peaked at $11.3K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.